Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
about
Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutationMechanisms underlying skin disorders induced by EGFR inhibitorsCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsPain related to cancer treatments and diagnostic procedures: a no man's land?Crizotinib-Induced Abnormal Signal Processing in the RetinaNeutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorCutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 PatientsRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option.Severe acneiform eruption induced by cetuximab (Erbitux).Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case reportDermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-AnalysisPredictive blood plasma biomarkers for EGFR inhibitor-induced skin rashChemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases.Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerSafety Profile and Clinical Recommendations for the Use of Lapatinib.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multiTreatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Unilateral onycholysis in a patient taking erlotinib (Tarceva).Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Role of erlotinib in the management of pancreatic cancer.Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Topical use of olive oil preparation to prevent radiodermatitis: results of a prospective study in nasopharyngeal carcinoma patients.Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report.Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 creamDermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform LesionsHigh vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas.Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.
P2860
Q26739096-E38C61C7-A2D5-426B-A5EA-837E5A8DF51EQ26745689-F3E6CD59-39EE-4034-8681-2758AEAD2845Q26781472-CF53A59C-F13E-4761-9D9A-01DD0DCFFA28Q27026749-4D5BF071-610B-4B66-B544-D676D5E52DF7Q28547218-48C70498-BE00-473A-A072-62A1AA13F995Q28728031-E2774C11-5ED1-438F-BB9E-2F701E569190Q29248067-F594A67A-3259-4881-8189-433F79F266ECQ30248499-C5EBC7A2-03A0-40B8-ACE2-C5A1F3BA170FQ33373495-25B5BB9C-54D9-4B84-8731-4B945D52B948Q33381285-DBD43E6E-EB42-47C0-80D7-9B46A0AB9506Q33445699-F4C9AAE4-4E8E-46FA-A4EA-B9BB9C82BE72Q33683529-066C60A0-F89A-41FE-855F-C62020535C2BQ33733218-7FBE362F-9C68-4652-B325-B8C4B7BE7108Q33754779-B2A558B0-269C-4351-8B6C-863B98FF8DEEQ33798783-96F72E6A-2949-4D2C-A792-B9A5CB460122Q33881510-77441555-EA99-49F4-82E4-1574DE38A182Q33895537-D4187E08-6E41-4E8C-86EC-2064CC0ED027Q33972047-E1728B43-A9E6-4050-8F1E-0DEA99436AADQ33983656-A941D795-BF37-4051-BCF9-D15C8086E70DQ34096239-4508EECD-49E8-4433-835A-4E34992EF3E4Q34272887-F842177F-A990-42BC-9D76-50123E0AA566Q34633455-79A3C185-7243-4248-B913-70380D288DA9Q34658519-887DC0DC-0116-4174-B518-3B488B633A45Q34820775-0C81DC78-C8B8-4440-A8CC-66205F365013Q35059625-780918B1-F2EE-4C09-BD3E-0F4BED03F44DQ35083960-1A7CF985-DC77-4B2C-BBB1-0C19B5A36F21Q35171463-61E615F6-6D61-4E12-A68E-55400C6956ECQ35584416-9010E1D2-73EB-4561-BAC5-A2EA47C3DDE5Q35913241-A6EF6491-3CE0-4EE5-804A-E779203D0C69Q35919264-1A5A75E8-3114-4E96-A726-27FAF7C4E30BQ35951086-4A7B136C-EDDB-4A4E-A8D5-B019DD379E15Q36012730-7450B58C-BC21-4041-8861-6DE33811BCD1Q36046400-F0163E50-EE08-4569-B67A-7D26B29CF024Q36084336-F3C61AD8-98FB-4824-9E04-895C2436F595Q36177683-47E77B54-51FE-47EF-973B-8BC9A13C87DBQ36246406-774070FF-DC96-4FFF-BA06-9B491EA15FA4Q36376880-9E092D35-639B-4AB0-83F2-245AEB0A2128Q36485041-4F4DEE13-3562-43C9-8B21-6151108BFAA3Q36537873-0B903E22-4C28-4F05-A74D-9A3C70B35F2BQ36635273-FEE553FD-3281-440B-A490-1205D414C7C2
P2860
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@ast
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@en
type
label
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@ast
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@en
prefLabel
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@ast
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@en
P356
P1433
P1476
Clinical signs, pathophysiolog ...... th factor receptor inhibitors.
@en
P2093
E Van Cutsem
P304
P356
10.1093/ANNONC/MDI279
P577
2005-07-12T00:00:00Z